Background: The recurrence of primary glomerulonephritis (GN) following kidney transplantation poses a significant threat to graft survival. To enhance kidney transplant outcomes, we must lessen the burden of recurrence. In recent years, there has been progress in understanding the incidence, risk factors for recurrence, pathophysiology, biomarkers, and therapeutics, making it worthwhile to conduct an update on primary GN that may recur following kidney transplantation. Summary: We conducted a narrative review of the literature on the novel discoveries of primary GN that can recur following kidney transplantation. To summarize, developing a broad consensus on recurrence diagnosis would greatly advance our understanding, and its development would be a valuable collaborative effort. The key risk factors for recurrence have been better understood, particularly in individuals with complement-related or monoclonal gammopathy-related recurrent membranoproliferative GN. Furthermore, we can identify better recurrent IgA nephropathy patients who are more likely to experience graft loss. New biomarkers for membranous nephropathy (anti-PLA2R-Ab) and focal and segmental glomerulosclerosis (anti-nephrin-Ab) can assist in identifying and monitoring patients at risk of recurrence. Regarding therapy, the focal and segmental glomerulosclerosis consensus will enhance recurrence treatment. Some complement inhibitors and anti-CD38 monoclonal antibodies are already promising in treating and healing recurrent C3 glomerulopathy and focal and segmental glomerulosclerosis, respectively. Finally, new drugs developed specifically to treat IgA nephropathy in the native kidney will also change the outcome of IgA nephropathy recurrence. Key Messages: Although there has been progress in understanding the recurrence of primary GN following kidney transplantation, a worldwide effort should be undertaken to gather research that will allow for improved diagnosis, monitoring, and management of these patients.

1.
Allen
PJ
,
Chadban
SJ
,
Craig
JC
,
Lim
WH
,
Allen
RDM
,
Clayton
PA
, et al
.
Recurrent glomerulonephritis after kidney transplantation: risk factors and allograft outcomes
.
Kidney Int
.
2017
;
92
(
2
):
461
9
.
2.
Briganti
EM
,
Russ
GR
,
McNeil
JJ
,
Atkins
RC
,
Chadban
SJ
.
Risk of renal allograft loss from recurrent glomerulonephritis
.
N Engl J Med
.
2002
;
347
(
2
):
103
9
.
3.
Cosio
FG
,
Cattran
DC
.
Recent advances in our understanding of recurrent primary glomerulonephritis after kidney transplantation
.
Kidney Int
.
2017
;
91
(
2
):
304
14
.
4.
Ponticelli
C
,
Glassock
RJ
.
Posttransplant recurrence of primary glomerulonephritis
.
Clin J Am Soc Nephrol
.
2010
;
5
(
12
):
2363
72
.
5.
Raina
R
,
Jothi
S
,
Haffner
D
,
Somers
M
,
Filler
G
,
Vasistha
P
, et al
.
Post-transplant recurrence of focal segmental glomerular sclerosis: consensus statements
.
Kidney Int
.
2024
;
105
(
3
):
450
63
.
6.
Uffing
A
,
Pérez-Sáez
MJ
,
Mazzali
M
,
Manfro
RC
,
Bauer
AC
,
de Sottomaior Drumond
F
, et al
.
Recurrence of FSGS after kidney transplantation in adults
.
Clin J Am Soc Nephrol
.
2020
;
15
(
2
):
247
56
.
7.
Uffing
A
,
Hullekes
F
,
Riella
LV
,
Hogan
JJ
.
Recurrent glomerular disease after kidney transplantation: diagnostic and management dilemmas
.
Clin J Am Soc Nephrol
.
2021
;
16
(
11
):
1730
42
.
8.
Shoji
J
,
Mii
A
,
Terasaki
M
,
Shimizu
A
.
Update on recurrent focal segmental glomerulosclerosis in kidney transplantation
.
Nephron
.
2020
;
144
(
Suppl 1
):
65
70
.
9.
Delville
M
,
Sigdel
TK
,
Wei
C
,
Li
J
,
Hsieh
SC
,
Fornoni
A
, et al
.
A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation
.
Sci Transl Med
.
2014
;
6
(
256
):
256ra136
.
10.
Shirai
Y
,
Miura
K
,
Ishizuka
K
,
Ando
T
,
Kanda
S
,
Hashimoto
J
, et al
.
A multi-institutional study found a possible role of anti-nephrin antibodies in post-transplant focal segmental glomerulosclerosis recurrence
.
Kidney Int
.
2024
;
105
(
3
):
608
17
.
11.
Jacobs-Cacha
C
,
Puig-Gay
N
,
Helm
D
,
Rettel
M
,
Sellares
J
,
Meseguer
A
, et al
.
A misprocessed form of Apolipoprotein A-I is specifically associated with recurrent focal segmental glomerulosclerosis
.
Sci Rep
.
2020
;
10
(
1
):
1159
.
12.
Angeletti
A
,
Bin
S
,
Magnasco
A
,
Bruschi
M
,
Cravedi
P
,
Ghiggeri
GM
.
Efficacy of combined rituximab and daratumumab treatment in posttransplant recurrent focal segmental glomerulosclerosis
.
Am J Transplant
.
2024
;
24
(
4
):
688
92
.
13.
Yu
CC
,
Fornoni
A
,
Weins
A
,
Hakroush
S
,
Maiguel
D
,
Sageshima
J
, et al
.
Abatacept in B7-1-positive proteinuric kidney disease
.
N Engl J Med
.
2013
;
369
(
25
):
2416
23
.
14.
Mühlbacher
T
,
Amann
K
,
Mahling
M
,
Nadalin
S
,
Heyne
N
,
Guthoff
M
.
Successful long-term management of recurrent focal segmental glomerulosclerosis after kidney transplantation with costimulation blockade
.
Clin Kidney J
.
2021
;
14
(
6
):
1691
3
.
15.
Delville
M
,
Baye
E
,
Durrbach
A
,
Audard
V
,
Kofman
T
,
Braun
L
, et al
.
B7-1 blockade does not improve post-transplant nephrotic syndrome caused by recurrent FSGS
.
J Am Soc Nephrol
.
2016
;
27
(
8
):
2520
7
.
16.
Kitchens
W
,
Farris
A
,
Pastan
S
,
Pearson
T
,
Larsen
C
,
Adams
A
.
Focal segmental glomerulosclerosis recurrence in renal transplant recipients treated with Belatacept
.
Am J Transplant
.
2017
;
17
(
Suppl 3
). https://atcmeetingabstracts.com/abstract/focal-segmental-glomerulosclerosis-recurrence-in-renal-transplant-recipients-treated-with-belatcept-2/ (accessed April 23, 2024).
17.
Boonpheng
B
,
Hansrivijit
P
,
Thongprayoon
C
,
Mao
SA
,
Vaitla
PK
,
Bathini
T
, et al
.
Rituximab or plasmapheresis for prevention of recurrent focal segmental glomerulosclerosis after kidney transplantation: a systematic review and meta-analysis
.
World J Transplant
.
2021
;
11
(
7
):
303
19
.
18.
Rheault
MN
,
Amaral
S
,
Bock
M
,
Chambers
ET
,
Chavers
B
,
Ters
ME
, et al
.
A randomized controlled trial of preemptive rituximab to prevent recurrent focal segmental glomerulosclerosis post-kidney transplant (PRI-VENT FSGS): protocol and study design
.
Front Nephrol
.
2023
;
3
:
1181076
.
19.
Shoji
J
,
Goggins
WC
,
Wellen
JR
,
Cunningham
PN
,
Johnston
O
,
Chang
SS
, et al
.
Efficacy and safety of bleselumab in preventing the recurrence of primary focal segmental glomerulosclerosis in kidney transplant recipients: a phase 2a, randomized, multicenter study
.
Transplantation
.
2024
;
108
(
8
):
1782
92
.
20.
Sethi
S
,
Fervenza
FC
.
Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification
.
Semin Nephrol
.
2011
;
31
(
4
):
341
8
.
21.
Caravaca-Fontán
F
,
Polanco
N
,
Villacorta
B
,
Buxeda
A
,
Coca
A
,
Ávila
A
, et al
.
Recurrence of immune complex and complement-mediated membranoproliferative glomerulonephritis in kidney transplantation
.
Nephrol Dial Transplant
.
2023
;
38
(
1
):
222
35
.
22.
Obata
S
,
Vaz de Castro
PAS
,
Riella
LV
,
Cravedi
P
.
Recurrent C3 glomerulopathy after kidney transplantation
.
Transplant Rev
.
2024
;
38
(
2
):
100839
.
23.
Golshayan
D
,
Schwotzer
N
,
Fakhouri
F
,
Zuber
J
.
Targeting the complement pathway in kidney transplantation
.
J Am Soc Nephrol
.
2023
;
34
(
11
):
1776
92
.
24.
Gonzalez Suarez
ML
,
Thongprayoon
C
,
Hansrivijit
P
,
Kovvuru
K
,
Kanduri
SR
,
Aeddula
NR
, et al
.
Treatment of C3 glomerulopathy in adult kidney transplant recipients: a systematic review
.
Med Sci
.
2020
;
8
(
4
):
44
.
25.
Garg
N
,
Zhang
Y
,
Nicholson-Weller
A
,
Khankin
EV
,
Borsa
NG
,
Meyer
NC
, et al
.
C3 glomerulonephritis secondary to mutations in factors H and I: rapid recurrence in deceased donor kidney transplant effectively treated with eculizumab
.
Nephrol Dial Transplant
.
2018
;
33
(
12
):
2260
5
.
26.
Wong
E
,
Nester
C
,
Cavero
T
,
Karras
A
,
Le Quintrec
M
,
Lightstone
L
, et al
.
Efficacy and safety of iptacopan in patients with C3 glomerulopathy
.
Kidney Int Rep
.
2023
;
8
(
12
):
2754
64
.
27.
Tarragon Estebanez
B
,
Bomback
AS
.
C3 glomerulopathy: novel treatment paradigms
.
Kidney Int Rep
.
2024
;
9
(
3
):
569
79
.
28.
Escudero-Saiz
VJ
,
Gonzalez
Á
,
García-Herrera
A
,
Larque
AB
,
Bomback
AS
,
Morantes
L
, et al
.
Factor B inhibition with iptacopan in recurrent C3 glomerulopathy following kidney transplant: a report of two cases
.
Kidney Med
.
2024
;
6
:
100823
.
29.
Sprangers
B
,
Hegenbart
U
,
Wetzels
JFM
.
Kidney transplantation in patients with monoclonal gammopathy of renal significance
.
Transplantation
.
2023
;
107
(
5
):
1056
68
.
30.
Al Jurdi
A
,
Cohen Bucay
A
,
Riella
LV
,
Yee
AJ
,
Abdelmalek
C
,
Klepeis
V
, et al
.
Successful treatment of posttransplant monoclonal gammopathy-associated C3 glomerulopathy with plasma cell clone-directed therapy
.
Transplant Direct
.
2024
;
10
(
5
):
e1616
.
31.
Said
SM
,
Cosio
FG
,
Valeri
AM
,
Leung
N
,
Sethi
S
,
Salameh
H
, et al
.
Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits is associated with high rate of early recurrence in the allograft
.
Kidney Int
.
2018
;
94
(
1
):
159
69
.
32.
Buxeda
A
,
Said
SM
,
Nasr
SH
,
Leung
N
,
El Ters
M
,
Cosio
FG
.
Recurrent proliferative glomerulonephritis with monoclonal immunoglobulin deposits in kidney allografts treated with anti-CD20 antibodies
.
Transplantation
.
2019
;
103
(
7
):
1477
85
.
33.
O’Shaughnessy
MM
,
Montez-Rath
ME
,
Lafayette
RA
,
Winkelmayer
WC
.
Patient characteristics and outcomes by GN subtype in ESRD
.
Clin J Am Soc Nephrol
.
2015
;
10
(
7
):
1170
8
.
34.
Moroni
G
,
Longhi
S
,
Quaglini
S
,
Gallelli
B
,
Banfi
G
,
Montagnino
G
, et al
.
The long-term outcome of renal transplantation of IgA nephropathy and the impact of recurrence on graft survival
.
Nephrol Dial Transplant
.
2013
;
28
(
5
):
1305
14
.
35.
Alachkar
N
,
Delsante
M
,
Greenberg
RS
,
Koirala
A
,
Alhamad
T
,
Abdalla
B
, et al
.
Evaluation of the modified Oxford score in recurrent IgA nephropathy in North American kidney transplant recipients: the banff recurrent glomerulonephritis Working Group report
.
Transplantation
.
2023
;
107
(
9
):
2055
63
.
36.
Uffing
A
,
Pérez-Saéz
MJ
,
Jouve
T
,
Bugnazet
M
,
Malvezzi
P
,
Muhsin
SA
, et al
.
Recurrence of IgA nephropathy after kidney transplantation in adults
.
Clin J Am Soc Nephrol
.
2021
;
16
(
8
):
1247
55
.
37.
Haas
M
;
International IgA Nephropathy Network and the Renal Pathology Society
.
Variability in diagnosis and treatment of recurrent IgA nephropathy in kidney transplants: results of surveys of renal pathologists and nephrologists
.
Kidney Int Rep
.
2023
;
8
(
11
):
2486
7
.
38.
Ortiz
F
,
Gelpi
R
,
Koskinen
P
,
Manonelles
A
,
Räisänen-Sokolowski
A
,
Carrera
M
, et al
.
IgA nephropathy recurs early in the graft when assessed by protocol biopsy
.
Nephrol Dial Transplant
.
2012
;
27
(
6
):
2553
8
.
39.
Li
Y
,
Tang
Y
,
Lin
T
,
Song
T
.
Risk factors and outcomes of IgA nephropathy recurrence after kidney transplantation: a systematic review and meta-analysis
.
Front Immunol
.
2023
;
14
:
1277017
.
40.
Avasare
RS
,
Rosenstiel
PE
,
Zaky
ZS
,
Tsapepas
DS
,
Appel
GB
,
Markowitz
GS
, et al
.
Predicting post-transplant recurrence of IgA nephropathy: the importance of crescents
.
Am J Nephrol
.
2017
;
45
(
2
):
99
106
.
41.
Aydin-Ghormoz
EA
,
Perlmutter
J
,
Koizumi
N
,
Ortiz
J
,
Faddoul
G
.
Outcomes of kidney transplantation in patients with IgA nephropathy based on induction: a UNOS data analysis
.
Clin Transplant
.
2024
;
38
(
1
):
e15225
.
42.
Gong
Z
,
Tang
J
,
Hu
W
,
Song
X
,
Liu
X
,
Mu
J
, et al
.
Serum galactose-deficient immunoglobulin A1 in recurrent immunoglobulin a nephropathy after kidney transplantation: a meta-analysis
.
Transpl Immunol
.
2023
;
79
:
101850
.
43.
Martín-Penagos
L
,
Benito-Hernández
A
,
San Segundo
D
,
Sango
C
,
Azueta
A
,
Gómez-Román
J
, et al
.
A proliferation-inducing ligand increase precedes IgA nephropathy recurrence in kidney transplant recipients
.
Clin Transplant
.
2019
;
33
(
4
):
e13502
.
44.
Rodrigo
E
,
Quintana
LF
,
Vázquez-Sánchez
T
,
Sánchez-Fructuoso
A
,
Buxeda
A
,
Gavela
E
, et al
.
Tubulo-interstitial inflammation increases the risk of graft loss after the recurrence of IgA nephropathy
.
Clin Kidney J
.
2024
;
17
(
1
):
sfad259
.
45.
Park
S
,
Baek
CH
,
Cho
H
,
Yu
MY
,
Kim
YC
,
Go
H
, et al
.
Glomerular crescents are associated with worse graft outcome in allograft IgA nephropathy
.
Am J Transplant
.
2019
;
19
(
1
):
145
55
.
46.
Park
S
,
Go
H
,
Baek
CH
,
Kim
YH
,
Kim
YC
,
Yang
SH
, et al
.
Clinical importance of the updated Oxford classification in allograft IgA nephropathy
.
Am J Transplant
.
2019
;
19
(
10
):
2855
64
.
47.
Bednarova
K
,
Mjøen
G
,
Hruba
P
,
Modos
I
,
Voska
L
,
Kollar
M
, et al
.
A novel prognostic nomogram predicts premature failure of kidney allografts with IgA nephropathy recurrence
.
Nephrol Dial Transplant
.
2023
;
38
(
11
):
2627
36
.
48.
Kidney Disease Improving Global Outcomes KDIGO Glomerular Diseases Work Group
.
KDIGO 2021 clinical practice guideline for the management of glomerular diseases
.
Kidney Int
.
2021
;
100
(
4S
):
S1
276
.
49.
Wheeler
DC
,
Toto
RD
,
Stefánsson
BV
,
Jongs
N
,
Chertow
GM
,
Greene
T
, et al
.
A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy
.
Kidney Int
.
2021
;
100
(
1
):
215
24
.
50.
Basic-Jukic
N
,
Juric
I
,
Furic-Cunko
V
,
Katalinic
L
.
The first experience with the use of dapagliflozin in combination with ACEi for treatment of IgA nephropathy after kidney transplantation
.
Int Urol Nephrol
.
2024
;
56
(
2
):
811
2
.
51.
Heerspink
HJL
,
Radhakrishnan
J
,
Alpers
CE
,
Barratt
J
,
Bieler
S
,
Diva
U
, et al
.
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
.
Lancet
.
2023
;
401
(
10388
):
1584
94
.
52.
Matsukuma
Y
,
Masutani
K
,
Tsuchimoto
A
,
Okabe
Y
,
Nakamura
M
,
Kitazono
T
, et al
.
Effect of steroid pulse therapy on post-transplant immunoglobulin A nephropathy
.
Nephrology
.
2018
;
23
(
Suppl 2
):
10
6
.
53.
Messina
M
,
di Vico
MC
,
Ariaudo
C
,
Mazzucco
G
,
Fop
F
,
Segoloni
GP
, et al
.
Treatment protocol with pulse and oral steroids for IgA Nephropathy after kidney transplantation
.
J Nephrol
.
2016
;
29
(
4
):
575
83
.
54.
Lopez-Martinez
M
,
Torres
I
,
Bermejo
S
,
Moreso
F
,
Garcia-Carro
C
,
Vergara
A
, et al
.
Enteric budesonide in transplant and native IgA nephropathy: real-world clinical practice
.
Transpl Int
.
2022
;
35
:
10693
.
55.
Gandolfini
I
,
Alibrandi
S
,
Gentile
M
,
Russo
LS
,
Fiaccadori
E
,
Palmisano
A
, et al
.
Targeted-release budesonide in recurrent IgA nephropathy after kidney transplantation
.
Kidney Int
.
2023
;
103
(
5
):
995
6
.
56.
El Karoui
K
,
Fervenza
FC
,
De Vriese
AS
.
Treatment of IgA nephropathy: a rapidly evolving field
.
J Am Soc Nephrol
.
2024
;
35
(
1
):
103
16
.
57.
Lafayette
R
,
Barbour
S
,
Israni
R
,
Wei
X
,
Eren
N
,
Floege
J
, et al
.
A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy
.
Kidney Int
.
2024
;
105
(
6
):
1306
15
.
58.
Sethi
S
,
Beck
LH
,
Glassock
RJ
,
Haas
M
,
De Vriese
AS
,
Caza
T
, et al
.
Mayo clinic consensus report on membranous nephropathy: proposal for a novel classification
.
Kidney Int
.
2023
;
98
(
11
):
1671
84
.
59.
Leon
J
,
Pérez-Sáez
MJ
,
Batal
I
,
Beck
LH
,
Rennke
HG
,
Canaud
G
, et al
.
Membranous nephropathy posttransplantation: an update of the pathophysiology and management
.
Transplantation
.
2019
;
103
(
10
):
1990
2002
.
60.
Passerini
P
,
Malvica
S
,
Tripodi
F
,
Cerutti
R
,
Messa
P
.
Membranous nephropathy (MN) recurrence after renal transplantation
.
Front Immunol
.
2019
;
10
:
1326
.
61.
Hullekes
F
,
Uffing
A
,
Verhoeff
R
,
Seeger
H
,
Von Moos
S
,
Mansur
J
, et al
.
Recurrence of membranous nephropathy after kidney transplantation: a multicenter retrospective cohort study
.
Am J Transplant
.
2024
;
24
(
6
):
1016
26
.
62.
Chung
EYM
,
Blazek
K
,
Teixeira-Pinto
A
,
Sharma
A
,
Kim
S
,
Lin
Y
, et al
.
Predictive models for recurrent membranous nephropathy after kidney transplantation
.
Transplant Direct
.
2022
;
8
(
9
):
e1357
.
63.
Panagakis
A
,
Bellos
I
,
Grigorakos
K
,
Panagoutsos
S
,
Passadakis
P
,
Marinaki
S
.
Recurrence of idiopathic membranous nephropathy in the kidney allograft: a systematic review
.
Biomedicines
.
2024
;
12
(
4
):
739
.
64.
Grupper
A
,
Cornell
LD
,
Fervenza
FC
,
Beck
LH
Jr
,
Lorenz
E
,
Cosio
FG
.
Recurrent membranous nephropathy after kidney transplantation: treatment and long-term implications
.
Transplantation
.
2016
;
100
(
12
):
2710
6
.
65.
Buxeda
A
,
Caravaca-Fontán
F
,
Vigara
LA
,
Pérez-Canga
JL
,
Calatayud
E
,
Coloma
A
, et al
.
High exposure to tacrolimus is associated with spontaneous remission of recurrent membranous nephropathy after kidney transplantation
.
Clin Kidney J
.
2023
;
16
(
10
):
1644
55
.
You do not currently have access to this content.